Tag: THE001
Thermosome Initiates Final Dose Level in Phase I Trial of Lead Compound THE001
— Independent Data Safety Monitoring Board declared dose level 2 as safe and recommended escalation to final dose level 3
Thermosome, a drug development company focused on targeted tumor therapies, today announced its ongoing Phase I trial has progressed to dose level 3 (DL3) after the independent Data Safety Monitoring Board (DSMB) declared dose level 2 (DL2) as safe and recommended escalation to the final dose level (DL3). In the trial, the Company’s lead compound THE001is tested in patients with heavily pre-treated, locally advanced unresectable or metastatic soft tissue sarcoma (STS) in combination with regional hyperthermia. Read more…
Thermosome Presents Encouraging Initial Clinical Data from Phase I Trial of Lead Compound THE001
— THE001 safe and well tolerated in first two dose level, demonstrating encouraging signs of clinical activity
— Data presented at The Connective Tissue Oncology Society (CTOS) Annual Meeting 2024
Thermosome, a drug development company focused on targeted tumor therapies, today announced encouraging initial clinical data from the ongoing Phase I study of its lead compound THE001 in patients with heavily pre-treated, locally advanced unresectable or metastatic soft tissue sarcoma (STS). The data were presented as a poster (#P410) titled “Phase I study of THE001 (DPPG2-TSL-DOX) combined with regional hyperthermia in patients with locally advanced or metastatic soft tissue sarcoma” at The Connective Tissue Oncology Society (CTOS) Annual Meeting 2024 in San Diego, USA. Read more…